Background: High-grade sarcomas harboring PDGFRB hotspot mutations with myogenic differentiation represent a recently characterized and aggressive subset of uterine sarcomas. First described by Dermawan et al, these tumors exhibit distinct morphological, immunophenotypic, and molecular profiles that differentiate them from conventional leiomyosarcomas. To date, only 13 gynecological tumors with this genetic alteration have been reported in the literature. Patient Presentation: We report a 56-year-old female patient who presented with a large uterine tumor with pulmonary metastases. Histological evaluation demonstrated a high-grade spindle cell neoplasm with exclusively myofibroblastic morphology and absence of key leiomyosarcoma morphological features. Immunohistochemistry showed diffuse and strong positivity for H-caldesmon and complete negativity for desmin, smooth muscle actin, myogenin, MYOD1, ALK, estrogen receptor, and progesterone receptor. Next-generation sequencing identified a PDGFRB hotspot in-frame deletion (c.2547_2558del; p.D850_R853del) along with co-occurring mutations in TP53, MED12, NOTCH3, and others. The tumor was clinically staged as FIGO Stage IVB due to lung metastases. The patient passed away 4 months after surgery. Conclusion: This tumor highlighted the importance of recognizing high-grade uterine sarcomas with PDGFRB hotspot mutations as a distinct diagnostic entity. Their aggressive clinical behavior, combined with unique histopathological and genetic features, underscores the need for molecular testing to ensure accurate diagnosis. Tyrosine kinase inhibitors such as imatinib may hold therapeutic promise, but further research is needed to optimize treatment strategies.
DermawanJKChiangSHensleyMLTapWDAntonescuCR. High-grade sarcomas with myogenic differentiation harboring hotspot PDGFRB mutations. Mod Pathol. 2023;36(5):100104. doi:https://doi.org/10.1016/j.modpat.2023.100104
2.
CheungYHGaydenTCampeauPM, et al.A recurrent PDGFRB mutation causes familial infantile myofibromatosis. Am J Hum Genet. 2013;92(6):996‐1000. doi:https://doi.org/10.1016/j.ajhg.2013.04.026
3.
MartignettiJATianLLiD, et al.Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis. Am J Hum Genet. 2013;92(6):1001‐1007. doi:https://doi.org/10.1016/j.ajhg.2013.04.024
4.
LinharesNFreireMCardenasR, et al.Modulation of expressivity in PDGFRB-related infantile myofibromatosis: a role for PTPRG. Genet Mol Res. 2014;13(3):6287‐6292.
5.
AgaimyABiegMMichalM, et al.Recurrent somatic PDGFRB mutations in sporadic infantile/solitary adult myofibromas but not in angioleiomyomas and myopericytomas. Am J Surg Pathol. 2017;41(2):195‐203.
6.
HungYPFletcherCD. Myopericytomatosis: clinicopathologic analysis of 11 cases with molecular identification of recurrent: pDGFRB: alterations in myopericytomatosis and myopericytoma. Am J Surg Pathol. 2017;41(8):1034‐1044.
7.
PakyariMMahadevanNRRussell-GoldmanE. Concurrent PTEN and PDGFRB alterations characterize storiform collagenoma. Am J Surg Pathol. 2024;48(2):150‐156.
8.
IwamuraRKomatsuKKusanoM, et al.PDGFRB and NOTCH3 mutations are detectable in a wider range of pericytic tumors, including myopericytomas, angioleiomyomas, glomus tumors, and their combined tumors. Mod Pathol. 2023;36(3):100070. doi:https://doi.org/10.1016/j.modpat.2022.100070
9.
WagnerMJPimentaEMSweeneyNW, et al.Genomic characterization of chondrosarcoma reveals potential therapeutic targets. JCO Precis Oncol. 2025;9:e2400592. doi:10.1200/po-24-00592
10.
ArtsFAChandDPecquetC, et al.PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib. Oncogene. 2016;35(25):3239‐3248. doi:10.1038/onc.2015.383
11.
PattisapuPWengerTLDahlJP, et al.Avoidance of surgery for head and neck infantile myofibromatosis using imatinib monotherapy. Clin Case Rep. 2022;10(2):e05382. doi:10.1002/ccr3.5382
12.
HensleyMLChavanSSSolitDB, et al.Genomic landscape of uterine sarcomas defined through prospective clinical sequencing. Clin Cancer Res. 2020;26(14):3881‐3888. doi:10.1158/1078-0432.Ccr-19-3959
13.
PapkeDJOdintsovIDicksonBCNucciMRAgaimyAFletcherCDM. Myxoid inflammatory myofibroblastic sarcoma: clinicopathologic analysis of 25 cases of a distinctive sarcoma with deceptively bland morphology and aggressive clinical behavior. Am J Surg Pathol. 2024;48(8):1005‐1016. doi:10.1097/pas.0000000000002231
